I-Flow Corporation Announces That Results of ON-Q Colorectal Study Will Be Presented at Infectious Diseases Conference in SeptemberLAKE FOREST, Calif.--(BUSINESS WIRE)--Aug 29, 2007 - I-Flow Corporation (NASDAQ:IFLO) announced today that results of its ON-Q prospective human study in colorectal surgery will be presented on Tuesday, September 18th at the world-renowned 47th Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC) in Chicago, Illinois.
The study was designed to explore the potential of ON-Q to reduce surgical site infections and to therefore expand ON-Q's clinical benefits beyond pain relief into the area of surgical site care. Today ON-Q is used to treat post-surgical pain in place of narcotics - yesterday's standard of care.
Abstracts that are presented at ICAAC, including the ON-Q study findings, are peer-reviewed and selected by the Society's esteemed faculty that is comprised of internationally renowned scientists. The ON-Q presentation was submitted as a "Late-Breaker" entry, a highly selective category of which only one of four entries is deemed notable enough to be presented. ICAAC attracts more than 12,000 attendees -- physicians, researchers and other healthcare professionals from around the world - who come together to foster solutions to the problem of infectious diseases.
The inherent risks and exceptionally high costs of caring for patients with surgical site infections has created a significant interest recently in the medical and investment communities around finding solutions to the problem. According to the Centers for Disease Control and Prevention's (CDC's) National Nosocomial Infections Surveillance (NNIS) system, surgical site infections often increase patient length of stay in the hospital by an average of seven or more days and cost the healthcare system hundreds of millions of dollars each year.
ON-Q is now labeled to significantly reduce pain better than narcotics and to significantly reduce narcotics intake after surgery. ON-Q therapy was recently upheld as a best practice for post-surgical pain relief and its widespread use was encouraged in an independent study published in the prestigious Journal of American College of Surgeons. The large-scale pain relief meta-analysis included 2,141 patients across a wide range of surgical procedures.
ON-Q is a simple yet elegant device that consists of a small balloon pump that holds a local anesthetic (a pain-numbing medicine) and delivers it automatically through a specially designed catheter to provide even distribution of local anesthetic over a wider area, as compared to other catheters, because of its patented wicking capabilities.
Currently, more than 55 studies on the use of ON-Q have been completed and published or presented and more are underway to demonstrate the benefits of ON-Q in additional areas such as reduced infection risk, combination therapies (e.g., local anesthetic and antibiotic mixtures, a combination of a local anesthetic and an anti-inflammatory), pediatrics and chronic pain. In addition, effective January 1, 2007, Medicare recognized the ON-Q therapy as a payable covered benefit and therefore medically necessary. To learn more about the benefits of ON-Q visit www.AskYourSurgeon.com.
I-Flow Corporation (www.IFLO.com) designs, develops and markets technically advanced, low cost drug delivery systems and services that are redefining the standard of care by providing life enhancing, cost effective solutions for pain relief.
"Safe Harbor" Statement
Statements by the Company in this press release and in other reports and statements released by the Company are and will be forward-looking in nature and express the Company's current opinions about trends and factors that may impact future operating results. Statements that use words such as "may," "will," "should," "believes," "predicts," "estimates," "projects," "anticipates" or "expects" or use similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to material risks, assumptions and uncertainties, which could cause actual results to differ materially from those currently expected, and readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, the Company undertakes no obligation to publish revised forward-looking statements to reflect the occurrence of unanticipated or subsequent events. Readers are also urged to carefully review and consider the various disclosures made by the Company in this press release that seek to advise interested parties of the risks and other factors that affect the Company's business. Interested parties should also review the Company's reports on Forms 10-K, 10-Q and 8-K and other reports that are periodically filed with or furnished to the Securities and Exchange Commission. The risks affecting the Company's business include, among others: successful consummation of the previously announced sale of InfuSystem, Inc; physician acceptance of infusion-based therapeutic regimens; implementation of the Company's direct sales strategy; dependence on the Company's suppliers and distributors; the Company's continuing compliance with applicable laws and regulations, such as the Medicare Supplier Standards and the Food, Drug and Cosmetic Act, and the Medicare's and FDA's concurrence with management's subjective judgment on compliance issues; the reimbursement system currently in place and future changes to that system; product availability, acceptance and safety; competition in the industry; technological changes; intellectual property challenges and claims; economic and political conditions in foreign countries; currency exchange rates; inadequacy of booked reserves; and reliance on the success of the home health care industry. All forward-looking statements, whether made in this release or elsewhere, should be considered in context with the various disclosures made by the Company about its business.
Orlando Rodrigues, 949-206-2619 (direct)
Posted: August 2007